Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51

Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51. An Uncontrolled Phase 3 Follow-up Study

The study investigates the long term safety and immunogenicity of the Japanese Encephalitis vaccine IC51 up to month 60.

Inclusion Criteria:

• Healthy subjects at least 18 years of age
• Written informed consent obtained prior to study entry
• Subjects correctly included and having completed clinical studies IC51-301 (NCT00604708) and IC51-302 (NCT00605085) with at least one vaccination

Exclusion Criteria:

• Inability or unwillingness to provide informed consent and to abide the requirements of the study